

CellDetect[®] Bladder

A unique and innovative urine - based test allowing color discrimination between normal and cancer cells alongside morphological examination


- Highly accurate
- Early detection
- Cost-effective
- Standard workflow
- Non-invasive

CellDetect® Bladder

CellDetect® Bladder — combining color and morphology

CellDetect® Bladder is a urine-based cytochemical staining test providing high-performance and cost-effectiveness in the detection of bladder tumors. It is the only cytochemical stain using color discrimination for flagging cancer cells, alongside morphological examination.

There is a real unmet need for a non-invasive, accurate and cost-effective solution for bladder cancer detection and surveillance



CellDetect® Bladder — breakthrough technology

Studies have shown that CellDetect® increases sensitivity in detecting bladder cancer (BC), as compared to standard cytology and other commercially available technologies. Due to its high sensitivity, CellDetect® increases accuracy of BC detection, in cases that wouldn't have been detected otherwise. CellDetect® will also optimize the number of invasive procedures required for recurrence monitoring.

Results of a multicenter blinded clinical study (n=217), 2015, Israel

	CellDetect®	Standard Cytology
Sensitivity	84%	50%
Specificity	83%	89%

Results of a prospective study (n=66), 2018, Germany*

	CellDetect®	Standard Cytology
Sensitivity	92%	46%
Specificity	80%	93%


* 12% of standard cytology cases were undetermined, out of which 90% of the cases were correctly diagnosed by CellDetect®

Bladder cancer – a global burden

With up to 80% recurrence, bladder cancer requires lifelong surveillance and is considered one of the most expensive cancers in terms of lifetime cost per patient. Detection and surveillance include cystoscopy, the current gold standard, an invasive and relatively expensive procedure associated with pain, discomfort, infection and low patient compliance and which is limited in the detection of flat urothelial lesions.

Micromedic Technologies (TASE: MCTC) is engaged in the development and commercialization of unique solutions addressing real needs prevailing in the field of cancer diagnostics and early cancer detection. CellDetect® is a Trademark of ZetiQ, a fully-owned subsidiary of Micromedic.

CellDetect® vs. Standard Cytology



	Standard Cytology	CellDetect®
Morphology	Yes	Yes
Color specific	No	Yes
Early detection	Low	High

- Increased clinical value
- Actionable results
- Cost-effective
- Easy to implement
- Standard lab processes / equipment



Bladder Cancer Facts | Europe

- 5th most common cancer in Europe
- 118,000 new cases annually
- 52,000 deaths annually
- €4.9 billion cost

Source: Globocan 2012

Importance of Early Detection

5-year survival rate decreases from 96% for patients with flat BC tumors, to 5.5% for patients with distant lesions

Source: SEER Cancer Stat 2014

References:
 2016; DOI: <https://doi.org/10.1016/j.euf.2016.10.004>
 Davis et al. Journal of Urology 2014; 192:1628-1632
 Idelevich et al. Diagnostic Cytopathology 2012; 40:1054-1061
 Sagiv et al. Journal of Carcinogenesis 2009; 8:16-23
 Davis et al. European Urology Focus



EC REP MedNet GmbH, Borkstrasse 10,
48163, Münster, Germany